Fund Holdings — Wildcat Capital Management, LLC

Total Portfolio Value
$187.39M
Total Bought
$20.73M
Total Sold
$1.25M
Net Transaction
+$19.48M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2024
▲▼
Q1 2025
▲▼
Change
▲▼
Q4 2024
▲▼
Q1 2025
▲▼
Weight (%)
▲▼
Change
▲▼
ACUREN CORP(TIC)01,500,000+1,500,000016,6808.90%+16,680
CENTESSA PHARMACEUTICALS PLC0281,859+281,85904,0532.16%+4,053
UROGEN PHARMA LTD(URGN)495,606495,60605,2785,4812.93%+203
SILEXION THERAPEUTICS CORP113,428113,42802281250.07%-103
KRONOS BIO INC1,297,9591,297,95901,2331,0710.57%-162
PROCORE TECHNOLOGIES INC(PCOR)8,0950-8,0956070—-607
GITLAB INC(GTLB)11,3990-11,3996420—-642
ALLOGENE THERAPEUTICS INC2,920,7872,920,78706,2214,2642.28%-1,957
RLX TECHNOLOGY INC(RLX)18,046,19518,046,195038,98033,92718.11%-5,053
FRONTIER GROUP HLDGS INC(ULCC)28,061,35128,061,3510199,516121,78664.99%-77,730
Page 1 of 1
Wildcat Capital Management, LLC — 13F Holdings — Q1 2025 | TickerTrail